회사 개요
SIGA Technologies, Inc. is a commercial-stage pharmaceutical entity that concentrates its operations on the health security market within the United States, leveraging a specialized portfolio to address specific disease threats. The company operates within the Healthcare sector and specifically functions in the Drug Manufacturers - Specialty & Generic industry, which implies a focus on niche therapeutic areas and potentially complex regulatory pathways distinct from mass-market consumer pharmaceuticals. At the time of analysis, the enterprise holds a market capitalization of $328.13M, generates annual revenue of $94.57M, and employs a workforce of 49 individuals. These valuation and financial scale figures indicate that SIGA maintains a relatively small market footprint compared to large-cap peers, yet it sustains profitability despite its limited employee base, suggesting a high-efficiency operational model or significant value derived from its lead product, TPOXX.
재무 건전성
The company reported revenue of $94.57M for the trailing twelve months, with a net income of $23.28M and EBITDA reaching $24.26M. The relationship between the revenue figure and the net income reveals a robust cost structure where the company successfully converts a significant portion of its top-line sales into bottom-line profit, achieving a profit margin of 24.6%. Furthermore, the free cash flow stands at $29.07M, which is notably higher than the net income, indicating strong cash generation capabilities that provide substantial financial flexibility for operations, R&D, or strategic acquisitions without immediate need for external capital. When analyzing the margin profile, the gross margin is reported at 47.5%, reflecting favorable pricing power or high-value inputs, while the operating margin shows a figure of -250.4%, a metric that requires careful interpretation in the context of potential one-time restructuring costs or specific accounting treatments for specialty drug development phases. Despite the wide operating margin variance, the profitability is confirmed by the positive net income and the ability to generate cash. In terms of leverage, the company holds $154.97M in cash against a debt load of $759,207, resulting in a debt-to-equity ratio of 0.38. This disparity between total cash and total debt demonstrates a highly conservative balance sheet with negligible leverage risk. Liquidity is exceptionally strong as evidenced by a current ratio of 11.83, which indicates the company possesses more than 11 times the current assets necessary to cover its short-term liabilities. Finally, the return on equity is 11.2% and the return on assets is 6.4%, metrics that collectively reveal management effectiveness in utilizing shareholder capital and the asset base to generate returns above the cost of capital.
밸류에이션 평가
Valuation metrics for SIGA Technologies, Inc. show a trailing P/E ratio of 14.31 and a forward P/E of 3.12. The substantial difference between these two ratios implies that the market expects earnings growth to accelerate significantly or that the current earnings base is elevated relative to future projections, potentially due to the cyclical nature of its revenue streams or specific accounting adjustments. The price-to-book ratio is 1.65, which indicates that the stock trades at a moderate premium over its book value, suggesting investors are willing to pay more for the company's tangible assets than their accounting replacement cost. Alternative valuation metrics such as the price-to-sales ratio of 3.47 and an EV/EBITDA of 7.17 provide additional context, suggesting the market values the company based on its sales efficiency and cash earnings power rather than just historical profits. Regarding price volatility, the 52-week high is $9.62 and the 52-week low is $4.56; assuming a trading price near the current market cap valuation context, the stock position relative to this range defines its recent momentum, though specific current price calculation requires the exact share price which is not explicitly listed as a single variable in the facts, only the range. The beta value is 1.06, which means the stock's price volatility is slightly higher than the broader market, indicating a sensitivity to general market movements that is marginally amplified compared to an index benchmark.
Growth & Income
The revenue growth year-over-year is recorded at -95.3%, while earnings growth is marked as N/A. The negative revenue growth rate indicates a contraction in top-line sales, which fundamentally alters the growth trajectory compared to the earnings situation where the absence of a growth rate figure suggests the earnings are not expanding at a comparable pace to historical norms, or the data point is unavailable for comparison. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, the earnings generated are not distributed to shareholders but are instead retained and reinvested into the business for growth initiatives, R&D, or to bolster the already substantial cash reserves. Consequently, the overall growth and income profile is characterized by a lack of dividend income for shareholders and a significant contraction in reported revenue, requiring investors to rely entirely on capital appreciation and the underlying value of the company's intellectual property and cash position for potential returns.